SU‐Eohyeol Pharmacopuncture Ameliorates Parkinson’s Disease–Associated Pain via the CB1 and PPARγ Pathways in an MPTP‐Induced Mouse Model
Pain Research and Management · 2026-01 · 2026 (1)
DOI: 10.1155/prm/3334432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pain Research and Management, online erschienen am 31.05.2026. Verfasst von Jung Im Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon, 34054, South Korea, kiom.re.kr. Hauptthemen laut MEDLINE: PPAR gamma, Receptor, Cannabinoid, CB1, Pain, Parkinsonian Disorders. Die Arbeit nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Institute of Oriental Medicine.
Abstract (Originalsprache)
Pain is a ubiquitous nonmotor symptom in Parkinson’s disease (PD), substantially impairing quality of life. Although pharmacological and surgical interventions provide partial relief, effective treatment for PD‐associated pain remains limited. Pharmacopuncture, an injection of herbal extracts into acupoints, has demonstrated potential in pain management. This study evaluated the analgesic and neuroprotective effects of SU‐Eohyeol pharmacopuncture (SUEHP) in a 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–induced PD mouse model. C57BL/6N male mice received repeated intraperitoneal injections of MPTP to induce PD‐related pain. SUEHP was bilaterally administered at the GB34 acupoint or a control site. Pain sensitivity and motor function were evaluated, followed by postsacrifice histological assessments. Administration of SUEHP at GB34 significantly attenuated MPTP‐induced mechanical hypersensitivity and spinal c‐Fos expression, enhanced tyrosine hydroxylase and brain‐derived neurotrophic factor expression in the substantia nigra, and partially restored motor function. However, cotreatment with a CB1 or PPARγ antagonist eliminated these analgesic and neuroprotective effects, suggesting that SUEHP mediates its effects through specific pathways. Transcriptomic profiling of the midbrain and spinal cord revealed that SUEHP modulated inflammation, dopaminergic neurogenesis, and synaptic signaling pathways, which were typically reversed using cotreatment with CB1 or PPARγ antagonist. Collectively, SUEHP alleviates PD‐associated pain and neurodegeneration through CB1 and PPARγ pathways, suggesting its potential as a safe, noninvasive complementary therapy for PD symptom management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon, 34054, South Korea, kiom.re.kr.
- College of Pharmacy, Chungnam National University, Daejeon, 34134, South Korea, cnu.ac.kr.
- KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, 34054, South Korea, kiom.re.kr.
ORCID-Profile: Jung Im Kim, Heerim Yeo, Yousang Jo, Hyungjun Kim, Sang-Min Park, No Soo Kim
Förderung
- Korea Institute of Oriental Medicine
Zitieren
APA
Kim, J. I., Yeo, H., Jo, Y., Kim, H., Park, S. M., & Kim, N. S. (2026). SU‐Eohyeol Pharmacopuncture Ameliorates Parkinson’s Disease–Associated Pain via the CB1 and PPARγ Pathways in an MPTP‐Induced Mouse Model. Pain Research and Management, 2026(1). https://doi.org/10.1155/prm/3334432
Vancouver
Kim JI, Yeo H, Jo Y, Kim H, Park SM, Kim NS. SU‐Eohyeol Pharmacopuncture Ameliorates Parkinson’s Disease–Associated Pain via the CB1 and PPARγ Pathways in an MPTP‐Induced Mouse Model. Pain Research and Management. 2026;2026(1). doi:10.1155/prm/3334432
BibTeX
@article{Kim2026,
author = {Kim, Jung Im and Yeo, Heerim and Jo, Yousang and Kim, Hyungjun and Park, Sang-Min and Kim, No Soo},
title = {SU‐Eohyeol Pharmacopuncture Ameliorates Parkinson’s Disease–Associated Pain via the CB1 and PPARγ Pathways in an MPTP‐Induced Mouse Model},
journal = {Pain Research and Management},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/prm/3334432}
}
EUVIMED